| Bioactivity | Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants[1][2]. |
| Invitro | Amubarvimab shows specific activity against wild-type SARS-CoV-2 and no cross-reactivity against other coronaviruses[1].Amubarvimab binds to two regions spanning amino acids 453-505 in the receptor-binding motif (RBM) and amino acids residues 403-421 in the core region of RBD[1]. |
| In Vivo | Amubarvimab (10-50 mg/kg; i.p.) in combination with romlusevimab significantly decreases viral load in the lungs, and reduces lung pathology in a Syrian golden hamster model of SARS-CoV-2 infection[1]. |
| Name | Amubarvimab |
| CAS | 2509447-07-6 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ji Y, et, al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435. [2]. Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drug. 2022 Aug;82(12):1327-1331. |